By continuing to use the site you agree to our Privacy & Cookies policy

Haemophilia prophylactic licensed

A prophylactic agent has been granted a license for haemophilia A patients with inhibitors.

Factor VIII Inhibitor Bypassing Activity (FEIBA) reduces a patient’s risk of spontaneous bleeds, minimising long-term complications, according to manufacturer Baxter. It is the first bypassing agent to be granted a prophylaxis indication for this group of patients.

Kate Khair, nurse consultant in haemophilia at Great Ormond Street Hospital in London, said: ‘Treating patients with inhibitors with FEIBA prophylaxis has a profound effect on the everyday life of a patient.’

Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!

newsletterpromo